Sikiric, P., Seiwerth, S., Grabarevic, Z., Rucman, R., Petek, M., Jagic, V., Turkovic, B., Rotkvic, I., Mise, S., Zoricic, I., Konjevoda, P., Perovic, D., Simicevic, V., Separovic, J., Hanzevacki, M., Ljubanovic, D., Artukovic, B., Bratulic, M., Tisljar, M., & Rekic, B
Compounded medications are prepared by state-licensed 503A pharmacies based on individual prescriptions and are not FDA-approved
It has never completed Phase III clinical trials and remains classified as a research compound
Zero adverse events across all groups No adverse events were reported in any of the three groups over the full 6-month treatment period
Table of Contents What Is a GLP-1 Plan